You are here

SPK-8011

Roche targets 2021 start for hemophilia A gene therapy phase 3 as optimization effort drags on

Roche targets 2021 start for hemophilia A gene therapy phase 3 as optimization effort drags on

Fierce Biotech

Spark Therapeutics

Flag link:

What's Next for Spark Therapeutics

What's Next for Spark Therapeutics

Motley Fool

Spark Therapeutics

Flag link:

3 Biotech Stocks With Major Catalysts Incoming

3 Biotech Stocks With Major Catalysts Incoming

Motley Fool

Spark Therapeutics

Progenics Pharmaceuticals

Flag link:

ASH17: Spark gene therapy falls behind BioMarin in hemophilia

ASH17: Spark gene therapy falls behind BioMarin in hemophilia

BioPharma Dive

Spark Therapeutics

Flag link:

Spark offers a glimpse of efficacy in first two hemophilia A gene therapy patients

Spark offers a glimpse of efficacy in first two hemophilia A gene therapy patients

Endpoints

Spark Therapeutics

Flag link: